Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on Jun 25, 2024 2:45pm
275 Views
Post# 36105537

Time's Up...

Time's Up...So, by now FDA will have responded to ONCY's Type C Meeting questions. Unlikely that they have exceeded the 75 day goal date.

So what does the absence of an announcement from ONCY portend..?  Well, if they were trying to get agreement on a biomarker (from FDA) to be used as a surrogate end-point, then it means Notable's spiel about Accelerated Approval is just talk.. it WON'T happen..

And how strange that Matt had a relapse just in time not to have to face the music... Oh btw, get well soon Matt.

So...  we've lost our Business Development lead, and now the CEO (Kirk Crook looks set to remain), but since we change CMO's every few years, I wonder if even Professor Heineken will be next to make a move...

 so, the ball is in your court now Mr Pisano... please do something, just anything with it...

hmmmm.. no news is bad news eh, until it is...
<< Previous
Bullboard Posts
Next >>